

Extraordinary Report

March 28, 2025

(TRANSLATION)

Note for readers of this English translation

On March 28, 2025, Chugai Pharmaceutical Co., Ltd. filed its Japanese-language Extraordinary Report (*Rinji Houkokusho*) with the Director-General of the Kanto Financial Bureau in Japan in connection with the Company's shareholders' voting results for proposals acted upon at the 114th Annual General Meeting of Shareholders held on March 27, 2025, pursuant to the Financial Instruments and Exchange Act of Japan. This document is an English translation of the Report.

1. Reason for submitting the Extraordinary Report

Given that resolutions were made for the proposals at the 114th Annual General Meeting of Shareholders (the "Meeting") held on March 27, 2025, Chugai Pharmaceutical Co., Ltd. (the "Company") submits this Extraordinary Report under the provisions of Article 24-5, Paragraph 4, of the Financial Instruments and Exchange Act of Japan and Article 19, Paragraph 2, Item 9-2, of the Cabinet Office Ordinance on Disclosure of Corporate Information, etc. (the "Report").

2. Contents of the Report

(1) Date when the Meeting was held; March 27, 2025

(2) Matters for resolution

First Proposal: Appropriation of Surplus

Year-end dividend

JPY 57 per share of common stock of the Company

Second Proposal: Election of Nine (9) Directors

Elect Osamu Okuda, Iwaaki Taniguchi, Hitoshi Ikura, Mariko Y Momoi, Fumio Tateishi, Hideo Teramoto, Thomas Schinecker, Teresa A. Graham and Boris L. Zaïtra as Directors of the Company.

Third Proposal: Election of One (1) Audit & Supervisory Board Member

Elect Masayoshi Higuchi as Audit & Supervisory Board Member of the Company.

(3) Number of voting rights concerning the indication of "for", "against" or "abstention" for each proposal; and Requirements for approving the proposals: Results of the resolutions

Proposal	For	Against	Abstention	Ratio of favorable votes	Results
First Proposal	15,192,302	39,425	31,605	99.53%	Approved
Second Proposal					
Osamu Okuda	12,657,489	2,570,972	34,842	82.93%	Approved
Iwaaki Taniguchi	14,678,184	575,843	9,285	96.17%	Approved
Hitoshi Iikura	14,679,001	575,027	9,285	96.17%	Approved
Mariko Y Momoi	14,754,605	497,579	11,134	96.67%	Approved
Fumio Tateishi	14,685,843	568,184	9,285	96.22%	Approved
Hideo Teramoto	14,739,101	514,931	9,285	96.57%	Approved
Thomas Schinecker	14,864,147	389,502	9,664	97.38%	Approved
Teresa A. Graham	14,693,522	560,506	9,285	96.27%	Approved
Boris L. Zaïtra	14,609,996	644,026	9,285	95.72%	Approved
Third Proposal	15,217,474	36,524	9,326	99.70%	Approved

Notes: Requirements for the approval of each proposal are as follows:

- 1) The resolution for the First Proposal must be adopted by the majority of the votes of the shareholders present who are entitled to exercise their voting rights.
 - 2) The resolution for the Second and the Third Proposals must be adopted by a majority of the votes of the shareholders present at the Meeting where the number of the voting rights of the shareholders present, amounts to one-third (1/3) or more.
- (4) Reason why a portion of the voting rights held by the shareholders present at the Meeting held on March 27, 2025, was not added to the number of voting rights

Because in terms of Japanese Companies Act, the required majority approval for each proposal was met by the votes exercised prior to the Meeting held on March 27, 2025, as well as the votes exercised by a portion of shareholders present and confirmed by the Company at the Meeting held on March 27, 2025; and the voting rights of the shareholders present at the Meeting held on March 27, 2025, untraceable with the final decision of "for", "against" or "abstention" as to each proposal were not tallied.